Altered uterine contractility in response to β-adrenoceptor agonists in ovarian cancer

• DOI: 10.1007/s12576-016-0500-1
• Publication Date: 2016-11-12T06:36:39Z
• Authors: Beata Modzelewska; Maciej Jóźwik; Marcin Jóźwik; Stanisław Sulkowski; Anna Pędzińska-Be...; Tomasz Kleszczewski; Anna Kostrzewska
• Keywords: Adult; Aged, 80 and over; Ovarian Neoplasms; 0301 basic medicine; Original Paper; Physiology; Adrenergic beta-3 Receptor Agonists; Dioxoles; Adrenergic beta-Agonists; Middle Aged; Endometrial Neoplasms; 3. Good health; Uterine Contraction; 03 medical and health sciences; Ethanolamines; Receptors, Adrenergic, beta; Humans; Female; Ritodrine; Aged

Abstract We aimed to prospectively examine β-adrenoceptor-mediated uterine contractility in women suffering from gynecological malignancies. Myometrial specimens were obtained from non-pregnant women undergoing hysterectomy for benign gynecological disorders, and ovarian, endometrial, synchronous ovarian–endometrial, and cervical cancer. Contractions of myometrial strips in an organ bath before and after cumulative dosages of β2- and β3-adrenoceptor agonists with preincubation of propranolol, SR 59230A, and butoxamine were studied. All agonists induced a dose-dependent attenuation for uterine contractility in endometrial or cervical cancer, similar to that observed in the reference group. Contradictory effects were observed for ovarian cancer alone or in combination with endometrial cancer. CL 316243 or ritodrine abolished the relaxation, whereas BRL 37344 increased the uterine contractility in ovarian cancer. Moreover, β-adrenoceptor antagonists caused varied effects for β2- or β3-adrenoceptor agonists. Our experiments demonstrate that ovarian cancer, alone or as synchronous ovarian–endometrial cancer, substantially alters uterine contractility in response to β-adrenoceptor agonists.